Skip to main content
. 2023 Jun 28;23:473. doi: 10.1186/s12888-023-04908-4

Table 1.

Changes in the number of antipsychotics/antidepressants for subjects with schizophrenia/major depression disorder

antipsychotics for subjects with schizophrenia*1 antidepressants for subjects with MDD*1
discharge discharge
monotherapy polypharmacy monotherapy polypharmacy
admission monotherapy 866 (41.3%) 260 (12.4%) 508 (62.4%) 78 (9.6%)
polypharmacy 254 (12.1%) 718 (34.2%) 92 (11.3%) 136 (16.7%)

MDD, Major depressive disorder; *1: p < 0.00001 (chi-squared test)